GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Medicine Co Ltd (SHSE:600216) » Definitions » Beneish M-Score

Zhejiang Medicine Co (SHSE:600216) Beneish M-Score : -2.39 (As of Apr. 16, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Zhejiang Medicine Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.39 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zhejiang Medicine Co's Beneish M-Score or its related term are showing as below:

SHSE:600216' s Beneish M-Score Range Over the Past 10 Years
Min: -3.33   Med: -2.56   Max: -2.14
Current: -2.39

During the past 13 years, the highest Beneish M-Score of Zhejiang Medicine Co was -2.14. The lowest was -3.33. And the median was -2.56.


Zhejiang Medicine Co Beneish M-Score Historical Data

The historical data trend for Zhejiang Medicine Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Medicine Co Beneish M-Score Chart

Zhejiang Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.44 -2.83 -2.36 -2.35 -2.51

Zhejiang Medicine Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.59 -2.51 -2.57 -2.48 -2.39

Competitive Comparison of Zhejiang Medicine Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Medicine Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Medicine Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Medicine Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Medicine Co's Beneish M-Score falls into.


;
;

Zhejiang Medicine Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zhejiang Medicine Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1014+0.528 * 0.8708+0.404 * 0.8023+0.892 * 1.1477+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0925+4.679 * 0.004638-0.327 * 0.9708
=-2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥2,040 Mil.
Revenue was 2707.337 + 2156.303 + 2249.164 + 1917.628 = ¥9,030 Mil.
Gross Profit was 1289.738 + 818.932 + 740.35 + 551.259 = ¥3,400 Mil.
Total Current Assets was ¥6,147 Mil.
Total Assets was ¥13,430 Mil.
Property, Plant and Equipment(Net PPE) was ¥6,183 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,267 Mil.
Total Current Liabilities was ¥2,358 Mil.
Long-Term Debt & Capital Lease Obligation was ¥373 Mil.
Net Income was 534.32 + 205.682 + 109.65 + 128.301 = ¥978 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 482.672 + 186.218 + 23.171 + 223.608 = ¥916 Mil.
Total Receivables was ¥1,614 Mil.
Revenue was 1938.576 + 1930.008 + 2007.935 + 1991.932 = ¥7,868 Mil.
Gross Profit was 640.292 + 655.001 + 677.715 + 606.919 = ¥2,580 Mil.
Total Current Assets was ¥5,496 Mil.
Total Assets was ¥12,593 Mil.
Property, Plant and Equipment(Net PPE) was ¥5,811 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,010 Mil.
Total Current Liabilities was ¥2,572 Mil.
Long-Term Debt & Capital Lease Obligation was ¥66 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2039.789 / 9030.432) / (1613.7 / 7868.451)
=0.225879 / 0.205085
=1.1014

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2579.927 / 7868.451) / (3400.279 / 9030.432)
=0.327882 / 0.376536
=0.8708

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6146.702 + 6183.055) / 13429.512) / (1 - (5496.405 + 5811.04) / 12592.866)
=0.081891 / 0.102075
=0.8023

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9030.432 / 7868.451
=1.1477

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 5811.04)) / (0 / (0 + 6183.055))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1266.54 / 9030.432) / (1010.097 / 7868.451)
=0.140252 / 0.128373
=1.0925

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((372.842 + 2358.145) / 13429.512) / ((65.548 + 2572.419) / 12592.866)
=0.203357 / 0.209481
=0.9708

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(977.953 - 0 - 915.669) / 13429.512
=0.004638

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zhejiang Medicine Co has a M-score of -2.39 suggests that the company is unlikely to be a manipulator.


Zhejiang Medicine Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zhejiang Medicine Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Medicine Co Business Description

Traded in Other Exchanges
N/A
Address
Comprehensive Building, No. 398 Mahuan Road, 3rd Floor, Building A, Binhai New City, Shaoxing, CHN, 312366
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
Executives
Zhu Jin Lin senior management
Chu Zhen Hua Director
Liang Bi Rong Director
Yu Yu Qing Director
Ping Jian Hong senior management
An Yong Bin senior management
Wang Xiao Ping senior management
Liang Li Ping senior management
Li Qi Rong senior management
Zhu Shao Ming Supervisors
Wang Hong Wei senior management
Zhang Ding Feng senior management
Ma Wen Xin Director
Zhao Jun Xing senior management
Lv Yong Hui Director

Zhejiang Medicine Co Headlines

No Headlines